Jill M. Taymans - 07 Jan 2026 Form 4 Insider Report for CRYO CELL INTERNATIONAL INC (CCEL)

Role: VP Finance, CFO
Signature: /s/ Jill Taymans
Issuer symbol: CCEL
Transactions as of: 07 Jan 2026
Net transactions value: +$106,200
Form type: 4
Filing time: 09 Jan 2026, 17:00:04 UTC
Previous filing: 23 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
TAYMANS JILL M	VP Finance, CFO	700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR	/s/ Jill Taymans	09 Jan 2026	0001261283

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CCEL	Common Stock						45,396	07 Jan 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCEL	Stock Option	Award	$35,400	+10,000		$3.54	10,000	07 Jan 2026	Common Stock	10,000	$3.54	Direct	F4
transaction	CCEL	Stock Option	Award	$70,800	+20,000		$3.54	20,000	07 Jan 2026	Common Stock	20,000	$3.54	Direct	F5
holding	CCEL	Stock Option						7,500	07 Jan 2026	Common Stock	7,500	$3.10	Direct
holding	CCEL	Stock Option						7,000	07 Jan 2026	Common Stock	7,000	$8.00	Direct	F1
holding	CCEL	Stock Option						20,000	07 Jan 2026	Common Stock	20,000	$4.62	Direct
holding	CCEL	Stock Option						10,000	07 Jan 2026	Common Stock	10,000	$5.88	Direct	F2
holding	CCEL	Stock Option						10,000	07 Jan 2026	Common Stock	10,000	$7.35	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Stock options vest 1/5 per year commencing on September 23, 2020.
F2	Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
F3	Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.
F4	Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.
F5	The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.